bioRxivBioinformaticsPreprint
maGENEgerZ: An Efficient AI-Based Framework Can Extract More Expressed Genes and Biological Insights Underlying Breast Cancer Drug Response Mechanism
Abstract
Understanding breast cancer drug response mechanism can play a crucial role in improving the treatment outcomes and survival rates. Existing bioinformatics-based approaches are far from perfect and do not adopt computational methods based on advanced artificial intelligence concepts. Therefore, we introduce a novel computational framework based on an efficient support vector machines (esvm) working as follows. First, we downloaded and processed three gene expression datasets related to breast cancer responding and non-responding to the treatments from the gene expression omnibus (GEO) according to the following GEO accession numbers: GSE130787, GSE140494, and GSE196093. Our method esvm is formulated as a constrained optimization problem in the dual form as a function of {lambda}. We recover the importance of each gene as a function of {lambda}, y, and x. Then, we select p genes out of n, provided as input to enrichment analysis tools, Enrichr and Metascape. Compared to existing baseline methods including deep learning, results demonstrate superiority and efficiency of esvm achieving high performance results and having more expressed genes in well-established breast cancer cell lines including MD-MB231, MCF7, and HS578T. Moreover, esvm is able to identify (1) various drugs including clinically approved ones (e.g., tamoxifen and erlotinib); (2) seventy-four unique genes (including tumor suppression genes such as TP53 and BRCA1); and (3) thirty-six unique TFs (including SP1 and RELA). These results have been reported to be linked to breast cancer drug response mechanism, progression, and metastasizing. Our method is available publicly in the maGENEgerZ web server at https://aibio.shinyapps.io/maGENEgerZ/.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- NSMCE2, a Novel Super-Enhancer Regulated Gene, is Linked to Poor Prognosis and Therapy Resistance in Breast Cancer
C. Di Benedetto, J. Oh, … P. Betancur·bioRxiv·Apr 1, 2022
- Fast and robust method for drug response biomarker identification and sample stratification.
Simanti Bhattacharya, Amit Kumar Das·bioRxiv·Jan 20, 2019
- BRDriver: Breast Cancer Driver Gene Predictor
Rajitha Perera, Roshan Priyarangana Perera·bioRxiv·Jan 9, 2023
- Novel two-stage deep learning-based approach applied to gene expression data pertaining to esophageal adenocarcinoma boosting biological knowledge discovery
Fahad Jamie, Turki Turki, … Y‐h. Taguchi·bioRxiv·Sep 18, 2026
- DriverGroup: A novel method for identifying drivergene groups
Vu Pham, Lin Liu, … Thuc Duy Le·BioinformaticsPeer-reviewed·Oct 20, 2020
- An Interpretable Machine Learning Framework for Early- versus Late-Stage Classification of Breast Cancer from Gene Expression, with Co-expression Network Analysis
Sriporna Biswas, Tanjidul Huda·bioRxiv·Oct 22, 2026